Kevetrin is the dark horse compound at this point. Who woulda' thought that three years ago :). The fact that there was any effect on P53 given Kevetrin was dosed once a week and it only stayed in the blood for a few hours is astounding. Increasing the dose and number of exposures could prove significantly beneficial.
I know management is still very high on Kevetrin but B and P are both closer to $$$ so smartly they are pushing those first. Plus any company that has signed CDA/NDAs for B and P are certainly going to be aware of Kevetrin. Once a partnership is created it will make for an easy path to revenue for other drugs and indications should CTIX choose to partner with the same company.
Everything will change if a partnership is announced.
Market Data 
Markets 
AI
